- Home
- SCNI vs QNRX Comparison
SCNI vs QNRX Comparison
Compare SCNI & QNRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SCNI
- QNRX
- Stock Information
- Founded
- SCNI 2003
- QNRX 2018
- Country
- SCNI Israel
- QNRX United States
- Employees
- SCNI N/A
- QNRX N/A
- Industry
- SCNI Biotechnology: Biological Products (No Diagnostic Substances)
- QNRX Medical/Dental Instruments
- Sector
- SCNI Health Care
- QNRX Health Care
- Exchange
- SCNI Nasdaq
- QNRX Nasdaq
- Market Cap
- SCNI 2.8M
- QNRX 2.5M
- IPO Year
- SCNI N/A
- QNRX N/A
- Fundamental
- Price
- SCNI $2.85
- QNRX $0.29
- Analyst Decision
- SCNI
- QNRX
- Analyst Count
- SCNI 0
- QNRX 0
- Target Price
- SCNI N/A
- QNRX N/A
- AVG Volume (30 Days)
- SCNI 10.1K
- QNRX 10.6M
- Earning Date
- SCNI 05-14-2025
- QNRX 03-13-2025
- Dividend Yield
- SCNI N/A
- QNRX N/A
- EPS Growth
- SCNI N/A
- QNRX N/A
- EPS
- SCNI 8.20
- QNRX N/A
- Revenue
- SCNI $452,000.00
- QNRX N/A
- Revenue This Year
- SCNI N/A
- QNRX N/A
- Revenue Next Year
- SCNI N/A
- QNRX N/A
- P/E Ratio
- SCNI $0.34
- QNRX N/A
- Revenue Growth
- SCNI N/A
- QNRX N/A
- 52 Week Low
- SCNI $2.23
- QNRX $0.21
- 52 Week High
- SCNI $8.92
- QNRX $1.57
- Technical
- Relative Strength Index (RSI)
- SCNI 34.84
- QNRX 49.51
- Support Level
- SCNI $2.64
- QNRX $0.21
- Resistance Level
- SCNI $2.86
- QNRX $0.32
- Average True Range (ATR)
- SCNI 0.25
- QNRX 0.03
- MACD
- SCNI -0.06
- QNRX -0.00
- Stochastic Oscillator
- SCNI 35.93
- QNRX 38.70
About SCNI Scinai Immunotherapeutics Ltd.
Scinai Immunotherapeutics Ltd is a biopharmaceutical company focused on developing, manufacturing and commercializing products for the prevention and treatment of infectious diseases and other illnesses. It has executed eight clinical trials in seven countries, around 12,400 participants in the Phase 3 trial of its vaccine candidate and has built a GMP biologics manufacturing facility for biopharmaceutical products. The company is aiming to develop a pipeline of diversified and commercially viable products and platforms beginning with a nanosized antibody (NanoAb) pipeline.
About QNRX Quoin Pharmaceuticals Ltd.
Quoin Pharmaceuticals Ltd is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Its pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, and others.